Deven Patel
Global Institute of Stem Cell Therapy and Research, USA
Keynote: Biochem Mol biol J
The field of stem cell research has come a long way from the early days of bone marrow transplant and progressed into sophisticated domain of autologous, allogeneic and embryonic stem cell and has largely escaped the risks faced during the emergence of genetic engineering. In fact, it has reached critical mass with several companies carrying out cutting edge research and several government organizations are recognizing the significant impact it would have in the well being of humanity with the promise of significant reduction of healthcare costs. We are already seeing evidence of positive impact on patients suffering from Autism, Alzheimer�s, MS, and Cerebral Palsy. And its only going to get better once the brilliant research meets the motivation of government and capital markets to bring this epoch-making technology to market and help cure degenerative diseases for the first time in human history.
Deven Patel, the CEO, President and Cofounder of Global Institute of Stem Cell Therapy and Research (GIOSTAR) with headquarter in San Diego, California, U.S.A. GIOSTAR was formed with the vision to provide affordable stem cell based therapies to the masses around the world suffering from degenerative or genetic diseases and unable to afford today’s high cost of the treatment. He was honored with USA Congressional Recognition for his efforts in spreading the advancement of stem cell science around the world. He was also bestowed upon Asian Heritage Award for his business leadership in the field of stem cell science. GIOSTAR under the leadership of Mr. Patel is in charge of developing stem cell transplant program for four different State Governments in India with total population of approx. 155 million. GIOSTAR, in collaborations with Government of Gujarat, India, world's largest state of the art Stem Cell Treatment Hospital in India.
Email:deven@giostar.com
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 